Abstract
The promotion of colonization with vancomycin-resistant enterococci (VRE) is one potential side effect during treatment of Clostridium difficile-associated diarrhea (CDAD), resulting from disturbances in gut microbiota. Cadazolid (CDZ) is an investigational antibiotic with potent in vitro activity against C. difficile and against VRE and is currently in clinical development for the treatment of CDAD. We report that CDZ treatment did not lead to intestinal VRE overgrowth in mice.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
MeSH terms
-
Aminoglycosides / pharmacology
-
Animals
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / adverse effects*
-
Clostridioides difficile / drug effects*
-
Clostridioides difficile / growth & development
-
Clostridioides difficile / pathogenicity
-
Colony Count, Microbial
-
Diarrhea / drug therapy*
-
Diarrhea / etiology
-
Diarrhea / microbiology
-
Diarrhea / pathology
-
Enterocolitis, Pseudomembranous / drug therapy*
-
Enterocolitis, Pseudomembranous / etiology
-
Enterocolitis, Pseudomembranous / microbiology
-
Enterocolitis, Pseudomembranous / pathology
-
Fidaxomicin
-
Intestines / drug effects
-
Intestines / microbiology
-
Intestines / pathology
-
Metronidazole / pharmacology
-
Mice
-
Microbial Sensitivity Tests
-
Oxazolidinones / pharmacology*
-
Streptococcal Infections / drug therapy
-
Streptococcal Infections / microbiology
-
Streptococcal Infections / pathology
-
Treatment Outcome
-
Vancomycin / administration & dosage
-
Vancomycin / adverse effects*
-
Vancomycin Resistance
-
Vancomycin-Resistant Enterococci / drug effects
-
Vancomycin-Resistant Enterococci / growth & development
-
Vancomycin-Resistant Enterococci / pathogenicity
Substances
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Oxazolidinones
-
Metronidazole
-
cadazolid
-
Vancomycin
-
Fidaxomicin